Retrophin, Inc. (NASDAQ:RTRX) was upgraded by analysts at TheStreet from a “d” rating to a “c-” rating in a research report issued on Friday, May 12th.
Several other brokerages also recently weighed in on RTRX. William Blair restated an “outperform” rating on shares of Retrophin in a research note on Thursday, April 6th. Zacks Investment Research downgraded Retrophin from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. Finally, BMO Capital Markets lowered their target price on Retrophin from $46.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, March 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.25.
Shares of Retrophin (NASDAQ:RTRX) traded up 1.91% during mid-day trading on Friday, hitting $18.10. The stock had a trading volume of 436,183 shares. The stock’s market cap is $690.93 million. Retrophin has a one year low of $15.55 and a one year high of $24.57. The firm has a 50 day moving average of $17.60 and a 200-day moving average of $18.98.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.23. The company had revenue of $33.62 million during the quarter, compared to the consensus estimate of $36.20 million. Retrophin had a negative return on equity of 3.74% and a negative net margin of 50.80%. The company’s revenue was up 15.9% on a year-over-year basis. During the same period last year, the firm earned $0.14 earnings per share. Equities research analysts expect that Retrophin will post ($1.14) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.com-unik.info/2017/06/17/retrophin-inc-rtrx-rating-increased-to-c-at-thestreet-updated-updated-updated.html.
Institutional investors have recently bought and sold shares of the company. Scopia Capital Management LP purchased a new position in Retrophin during the third quarter worth approximately $95,180,000. Russell Investments Group Ltd. purchased a new position in Retrophin during the fourth quarter worth approximately $387,000. Bogle Investment Management L P DE increased its position in Retrophin by 458.5% in the fourth quarter. Bogle Investment Management L P DE now owns 200,196 shares of the biopharmaceutical company’s stock worth $3,789,000 after buying an additional 164,349 shares during the period. Paulson & CO. Inc. purchased a new position in Retrophin during the fourth quarter worth approximately $1,041,000. Finally, Boston Advisors LLC increased its position in Retrophin by 24.4% in the first quarter. Boston Advisors LLC now owns 230,005 shares of the biopharmaceutical company’s stock worth $4,246,000 after buying an additional 45,050 shares during the period.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
What are top analysts saying about Retrophin Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Retrophin Inc. and related companies.